

**From:** [REDACTED]@gsk.com>  
**Sent:** mardi 14 avril 2020 13:06  
**To:** BUCHER Anne (SANTE); SEYCHELL Martin (SANTE)  
**Cc:** [REDACTED]@sanofi.com; [REDACTED]@sanofi.com  
**Subject:** Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19  
**Attachments:** Press Release - Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 14042020.pdf  
**Categories:** A voir par

Dear Mrs Bucher and Mr Seychell,

Today, Sanofi and GSK announce we are entering into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Definitive terms of the collaboration are expected to be finalised over the next few weeks.

Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. GSK will contribute its proven pandemic adjuvant technology to the collaboration. We plan to initiate phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for licensure [REDACTED]

Considering the extraordinary humanitarian and financial challenge of the pandemic, both companies believe that global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public and through mechanisms that offer fair access for people in all countries.

It is clear no one company can address COVID-19 alone and we are proud that this collaboration brings together two of the world's largest vaccines companies.

The press release announcing this news is attached; please feel free to reach out if you have any questions.

- GSK: [REDACTED]@gsk.com
- Sanofi Pasteur: [REDACTED]@sanofi.com

We have also informed President von der Leyen and Commissioners Kyriakides, Breton, Gabriel and Lenarčič.

Best wishes,

[REDACTED]

[REDACTED]

Communications and Government Affairs, Vaccines

**GSK**

20, Avenue Fleming, Building W23, 1300 Wavre, Belgium

**Email:** [REDACTED]@gsk.com

**Mobile:** [REDACTED] **Tel (landline):** [REDACTED]

[gsk.com](http://gsk.com) | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)



**GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.**